Asklepios BioPharmaceutical (AskBio) has bought Synpromics bringing gene control synthetic promoter technology to its AAV gene therapy programs. Under terms of the deal, Edinburgh, UK-based Synpromics will will bring synthetic promoter technology, along with bioinformatics and intelligent data-driven design, to North Carolina’s AskBio’s gene therapy pipeline. AskBio has its own capsid library and a proprietary adeno-associated virus (AAV) manufacturing platform called Pro10 which it uses in its gene therapies. Its lead candidate is in Phase I/II for Pompe Disease. “For…